HC Wainwright Lowers Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Krystal Biotech in a research note issued to investors on Monday, June 30th. HC Wainwright analyst J. Pantginis now expects that the company will earn $1.26 per share for the quarter, down from their previous forecast of $1.71. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2025 earnings at $1.58 EPS, Q4 2025 earnings at $2.12 EPS and FY2025 earnings at $5.71 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%.

Several other analysts have also recently issued reports on the company. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup decreased their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Finally, Guggenheim decreased their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $211.13.

Krystal Biotech Stock Performance

Shares of KRYS traded up $1.66 during mid-day trading on Wednesday, hitting $143.01. 168,281 shares of the stock were exchanged, compared to its average volume of 287,292. The company has a market cap of $4.13 billion, a PE ratio of 34.38 and a beta of 0.67. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $219.34. The firm has a 50-day moving average of $138.07 and a two-hundred day moving average of $156.77.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of KRYS. Brooklyn Investment Group increased its position in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares during the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the 1st quarter valued at approximately $29,000. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after acquiring an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Krystal Biotech in the 1st quarter valued at $74,000. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).